Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 1-5, 14, 17, 24, 29, 48-51, 54-57, 61, 62, 63, 66-72, 79,82, 89, 94, 107, 110, 121, 127, 128, 129, 132, 133, 135, 136 and 139 are currently pending in the instant application. Applicants have amended claims 4-5, 14, 17, 24, 29, 51, 54-57, 63, 70-72, 79, 82, 89, 94, 107, 110, 121, 129, 132-133, 135-136 and 139 and canceled claims 6-13, 15-16, 18-23, 25-28, 30-47, 52-53, 58-60, 64-65, 73-78, 80-81, 83-88, 90-93, 95-106, 108-109, 111-120, 122-126, 130-131, 134, 137-138 and 140-154 in an amendment filed on November 14, 2024. Claims 1, 4, 5, 14, 17, 24, 132, 133, 135, 136 and 139 are rejected, claims 29, 48, 51, 54-57, 61-63, 66-72, 79, 82, 89, 94, 107, 110, 121 and 127-129 are objected and claims 2, 3, 49 and 50 are considered allowable in this Office Action.
I. Priority
The instant application claims benefit of US Provisional Application 63/653,388, filed on May 30, 2024 and 63/516, 579, filed on July 31, 2023.
II. Information Disclosure Statement
The information disclosure statements (IDS) submitted on March 27, 2025, December 5, 2025 and May 22, 2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner.
III. Rejections
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless -
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1, 4, 5, 14, 17, 24, 132, 133, 135, 136 and 139 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Li, et al. (WO 2020/156363 A1). The instant invention claims
PNG
media_image1.png
783
728
media_image1.png
Greyscale
PNG
media_image2.png
781
632
media_image2.png
Greyscale
PNG
media_image3.png
808
616
media_image3.png
Greyscale
The Li, et al. reference teaches STING agonists such as
PNG
media_image4.png
276
470
media_image4.png
Greyscale
(See page 15, first compound in the right column) wherein R1a and R1b are hydrogen; R2a is
PNG
media_image5.png
114
81
media_image5.png
Greyscale
; R2b is
PNG
media_image6.png
82
94
media_image6.png
Greyscale
; L1 is
PNG
media_image7.png
43
32
media_image7.png
Greyscale
; R20 is
PNG
media_image8.png
75
74
media_image8.png
Greyscale
; L2 is
PNG
media_image9.png
52
72
media_image9.png
Greyscale
; A1 is
PNG
media_image10.png
70
116
media_image10.png
Greyscale
and the use of these compounds for inhibiting multiple tumors. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above.
Claims 1, 4, 5, 14, 17, 24, 132, 133, 135, 136 and 139 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Peng, et al. (WO 2021/013250 A1). The instant invention claims
PNG
media_image1.png
783
728
media_image1.png
Greyscale
PNG
media_image2.png
781
632
media_image2.png
Greyscale
PNG
media_image3.png
808
616
media_image3.png
Greyscale
The Peng, et al. reference teaches STING agonists such as
PNG
media_image11.png
224
228
media_image11.png
Greyscale
(See page 15, first compound in the right column) wherein R1a and R1b are hydrogen; R2a and R2b are
PNG
media_image5.png
114
81
media_image5.png
Greyscale
; L1 is
PNG
media_image7.png
43
32
media_image7.png
Greyscale
; R20 is
PNG
media_image8.png
75
74
media_image8.png
Greyscale
; L2 is
PNG
media_image9.png
52
72
media_image9.png
Greyscale
; A1 is
PNG
media_image12.png
60
58
media_image12.png
Greyscale
and the use treating disease mediated by STING protein. This species of compound anticipates the genus compound of the instant invention, wherein the genus structure and its definitions are stated above.
IV. Objections
Dependent Claim Objections
Dependent Claims 29, 48, 51, 54, -57, 61-63, 66-72, 79, 82, 89, 94, 107, 110, 121 and 127-129 are objected to as being dependent upon a rejected based claim. To overcome this objection, Applicant should rewrite said claims in an independent form and include the limitations of the base claim and any intervening claim.
V. Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Prosecution Insights